Guggenheim Lifts Tenet Healthcare (THC) Price Target to $283

Tenet Healthcare Corporation (NYSE:THC) is one of the 11 Best Stocks You’ll Wish You Bought Sooner.

Guggenheim Lifts Tenet Healthcare (THC) Price Target to $283

On March 12, 2026, Guggenheim increased the price target on Tenet Healthcare Corporation (NYSE:THC) from $271 to $283 and kept a Buy rating on the stock. In addition to the 90% return reported by the company, the firm identifies a few more reasons that validate its price target adjustment. This includes the analyst’s description of the first quarter as an “easy set-up” due to conservative guidance. The firm also views the projected 10% core EBITDA growth for 2026 as a manageable hurdle when compared to Tenet Healthcare Corporation (NYSE:THC)’s historical outlook or expectations.

In a separate event that day, Mizuho raised its price target on Tenet Healthcare Corporation (NYSE:THC) from $235 to $265. The firm maintained its Outperform rating on the company’s stock. This update follows the company’s Q4 report. The firm’s analyst anticipates the company will benefit from a positive demographic shift toward an aging population and a focus on higher-acuity surgeries.

Founded in 1969, Tenet Healthcare Corporation (NYSE:THC) is a diversified healthcare services company. Based in Texas, the company operates through the Hospital Operations and Ambulatory Care segments.

READ NEXT: 10 Best Diagnostics and Research Stocks to Buy According to Analysts and 15 Set-It-and-Forget-It Stocks to Buy in 2026

Disclosure: None.  Follow Insider Monkey on Google News.